APGE Valuation

Apogee Therapeutics Inc

Add to Watchlist

Advanced Chart

36.370

-0.25(-0.683%)1D

Overview
Forecast
Valuation
Earnings

APGE Relative Valuation

APGE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APGE is overvalued; if below, it's undervalued.

Historical Valuation

Apogee Therapeutics Inc (APGE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -12.28. The fair price of Apogee Therapeutics Inc (APGE) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：36.34

Fair

-6.92

Trailing

Forward

-4.92

EV/EBITDA

Apogee Therapeutics Inc. (APGE) has a current EV/EBITDA of -4.92. The 5-year average EV/EBITDA is -6.29. The thresholds are as follows: Strongly Undervalued below -15.60, Undervalued between -15.60 and -10.95, Fairly Valued between -1.64 and -10.95, Overvalued between -1.64 and 3.01, and Strongly Overvalued above 3.01. The current Forward EV/EBITDA of -4.92 falls within the Historic Trend Line -Fairly Valued range.

-4.44

EV/EBIT

Apogee Therapeutics Inc. (APGE) has a current EV/EBIT of -4.44. The 5-year average EV/EBIT is -8.55. The thresholds are as follows: Strongly Undervalued below -16.12, Undervalued between -16.12 and -12.33, Fairly Valued between -4.76 and -12.33, Overvalued between -4.76 and -0.98, and Strongly Overvalued above -0.98. The current Forward EV/EBIT of -4.44 falls within the Overvalued range.

0.00

Apogee Therapeutics Inc. (APGE) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-9.94

P/OCF

Apogee Therapeutics Inc. (APGE) has a current P/OCF of -9.94. The 5-year average P/OCF is -14.30. The thresholds are as follows: Strongly Undervalued below -24.94, Undervalued between -24.94 and -19.62, Fairly Valued between -8.98 and -19.62, Overvalued between -8.98 and -3.66, and Strongly Overvalued above -3.66. The current Forward P/OCF of -9.94 falls within the Historic Trend Line -Fairly Valued range.

-8.87

P/FCF

Apogee Therapeutics Inc. (APGE) has a current P/FCF of -8.87. The 5-year average P/FCF is -14.71. The thresholds are as follows: Strongly Undervalued below -25.06, Undervalued between -25.06 and -19.89, Fairly Valued between -9.53 and -19.89, Overvalued between -9.53 and -4.35, and Strongly Overvalued above -4.35. The current Forward P/FCF of -8.87 falls within the Overvalued range.

Apogee Therapeutics Inc (APGE) has a current Price-to-Book (P/B) ratio of 3.46. Compared to its 3-year average P/B ratio of 3.09 , the current P/B ratio is approximately 11.95% higher. Relative to its 5-year average P/B ratio of 3.09, the current P/B ratio is about 11.95% higher. Apogee Therapeutics Inc (APGE) has a Forward Free Cash Flow (FCF) yield of approximately -10.24%. Compared to its 3-year average FCF yield of -5.41%, the current FCF yield is approximately 89.26% lower. Relative to its 5-year average FCF yield of -5.41% , the current FCF yield is about 89.26% lower.

3.44

P/B

Median3y

3.09

Median5y

3.09

-10.56

FCF Yield

Median3y

-5.41

Median5y

-5.41

Competitors Valuation Multiple

The average P/S ratio for APGE's competitors is 1409.16, providing a benchmark for relative valuation. Apogee Therapeutics Inc Corp (APGE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

APGE.O

Apogee Therapeutics Inc

Denali Therapeutics Inc

Recursion Pharmaceuticals Inc

Performance Decomposition

Market capitalization of APGE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of APGE in the past 1 year is driven by Unknown.